Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock
Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities ...
Newswire17d
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, recently shared its Q4 2024 and FY ...
C&EN19d
A Semiconducting Polymer NanoCRISPR for Near-Infrared Photoactivatable Gene Editing and Cancer Gene Therapy
State Key Laboratory of Physical Chemistry of Solid Surfaces, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China ...
Frontiers22d
Centrosomes and associated proteins in pathogenesis and treatment of breast cancer
CDK1/Cyclin B interacts with Aurora kinase A to enhance its phosphorylation and activation of PLK1. Aurora kinase A activity is inhibited by BRCA1. PLK1 induces CDC25C activation and WEE1 degradation ...
The EMBO Journal23d
PLK1 inhibition delays mitotic entry revealing changes to the phosphoproteome of mammalian cells early in division
Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Polo-like kinase 1 (PLK1) is a conserved ...
TMCnet26d
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
Company will hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company ...
Nasdaq26d
Cardiff Oncology Reports Positive Initial Efficacy Data for Onvansertib in Metastatic Colorectal Cancer and Secures $40 Million Financing
About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range ...
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer (“mCRC”) clinical trial (CRDF-004) - - Priced oversubscribed $40 million ...
Investing26d
Earnings call transcript: Cardiff Oncology Q4 2024 highlights strategic advances
Cardiff Oncology Inc. (CRDF) has reported its financial results for the fourth quarter of 2024, revealing a strategic focus on its lead program and a strong cash position. The company’s ...
Yahoo Finance26d
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of ...
Frontiers27d
Dehydrodiisoeugenol targets the PLK1-p53 axis to inhibit breast cancer cell cycle
Results: Our research showed that DHIE and breast cancer enriched core gene targets mainly act on epithelial cells in breast cancer tissues and significantly inhibit the growth of breast cancer by ...